ENG/中
老虎证券
行情
产品介绍
Cash Boost账户
美股
美股碎股
港股
A股通
期权
期货
美国国债
定投
固定票息票据
Tiger BOSS Debit Card
基金超市
老虎钱袋子
老虎API平台
Wealth
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
专栏
TigerAI
机构
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
登录
立即注册
Toggle
美股
详情
本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务
The Nightview Fund
26.67
+0.0282
0.11%
成交量:
946.00
成交额:
2.53万
市值:
2,250.68万
市盈率:
- -
高:
26.80
开:
26.66
低:
26.66
收:
26.65
数据加载中...
总览
公司
新闻
公告
公司资料
公司名字:
The Nightview Fund
交易所:
ARCA
成立时间:
2018
员工人数:
- -
公司地址:
10900 Hefner Pointe Drive,Suite 400,Oklahoma City,Oklahoma,United States
官网:
http://www.nightstartx.com
邮编:
73120
电话:
405-778-8377
传真:
405-896-5825
简介:
Nightstar Therapeutics Plc最初于2013年5月根据英格兰和威尔士的法律成立,随后于2014年1月更名为NightstaRx Limited。该公司是一家领先的临床阶段基因治疗公司,专注于开发和治疗药物患有罕见的遗传性视网膜疾病,否则会进入失明。利用他们在眼科,基因治疗和药物开发方面的专业知识,他们正在开发一系列专有产品候选人,旨在大幅度修改或停止目前尚未批准的治疗的遗传性视网膜疾病的进展。他们的任务是维护和通过构建领先的垂直整合视网膜基因治疗公司,恢复患者的视力。
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/NITE/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NITE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NITE\",,,,,undefined,":{"symbol":"NITE","market":"US","secType":"STK","nameCN":"The Nightview Fund","latestPrice":26.6742,"timestamp":1745870400000,"preClose":26.646,"halted":0,"volume":946,"delay":0,"floatShares":843768,"shares":843768,"eps":0,"marketStatus":"盘前交易","change":0.0282,"latestTime":"04-29 05:33:32 EDT","open":26.66,"high":26.8036,"low":26.66,"amount":25271.87,"amplitude":0.005389,"askPrice":42.41,"askSize":100,"bidPrice":10.73,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1745933400000},"marketStatusCode":1,"adr":1,"adrRate":1,"listingDate":1506571200000,"exchange":"ARCA","adjPreClose":26.6742,"sharesOutstanding":843768,"nav":26.63,"aum":22472299.01,"bidAskSpread":0,"volumeRatio":0.3894927728669025},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NITE\",,,,,undefined,":{"symbol":"NITE","floatShares":843768,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.3894927728669025,"shares":843768,"dividePrice":0,"high":26.8036,"amplitude":0.005389,"preClose":26.646,"low":26.66,"week52Low":22.21,"pbRate":"--","week52High":31.89,"institutionHeld":0,"latestPrice":26.6742,"eps":0,"divideRate":0,"volume":946,"delay":0,"ttmEps":0,"open":26.66,"prevYearClose":29.87,"prevWeekClose":26.646,"prevMonthClose":26.3266,"prevQuarterClose":26.3266,"fiveDayClose":23.6087,"twentyDayClose":26.3889,"sixtyDayClose":31.5235},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":1858671235,"yearFounded":2018,"address":"10900 Hefner Pointe Drive,Suite 400,Oklahoma City,Oklahoma,United States","zipCode":"73120","officePhone":"405-778-8377","officeFax":"405-896-5825"},"stockCompanyDetail":{"websiteUrl":"http://www.nightstartx.com","stockEarnings":[{"period":"1week","weight":0.1298},{"period":"1month","weight":0.0108},{"period":"3month","weight":-0.1395},{"period":"6month","weight":-0.0146},{"period":"1year","weight":0.0633},{"period":"ytd","weight":-0.107}],"compareEarnings":[{"period":"1week","weight":0.0719},{"period":"1month","weight":-0.0087},{"period":"3month","weight":-0.0888},{"period":"6month","weight":-0.0503},{"period":"1year","weight":0.0838},{"period":"ytd","weight":-0.0601}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Nightstar Therapeutics Plc最初于2013年5月根据英格兰和威尔士的法律成立,随后于2014年1月更名为NightstaRx Limited。该公司是一家领先的临床阶段基因治疗公司,专注于开发和治疗药物患有罕见的遗传性视网膜疾病,否则会进入失明。利用他们在眼科,基因治疗和药物开发方面的专业知识,他们正在开发一系列专有产品候选人,旨在大幅度修改或停止目前尚未批准的治疗的遗传性视网膜疾病的进展。他们的任务是维护和通过构建领先的垂直整合视网膜基因治疗公司,恢复患者的视力。","exchange":"ARCA","name":"The Nightview Fund","nameEN":"The Nightview Fund"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"NITE\",market:\"US\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NITE\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NITE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NITE\",market:\"US\",delay:false,,,undefined,":{}}}